1.705
前日終値:
$1.91
開ける:
$1.8
24時間の取引高:
1.09M
Relative Volume:
0.74
時価総額:
$120.98M
収益:
-
当期純損益:
$-117.50M
株価収益率:
-0.7104
EPS:
-2.4
ネットキャッシュフロー:
$-114.31M
1週間 パフォーマンス:
-13.45%
1か月 パフォーマンス:
+5.25%
6か月 パフォーマンス:
-56.28%
1年 パフォーマンス:
-82.02%
Nkarta Inc Stock (NKTX) Company Profile
名前
Nkarta Inc
セクター
電話
(925) 407-1049
住所
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
NKTX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
NKTX
Nkarta Inc
|
1.705 | 120.98M | 0 | -117.50M | -114.31M | -2.40 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-10-09 | 開始されました | Rodman & Renshaw | Buy |
2024-08-14 | アップグレード | Raymond James | Outperform → Strong Buy |
2024-03-22 | ダウングレード | Raymond James | Strong Buy → Outperform |
2022-12-22 | ダウングレード | Oppenheimer | Outperform → Perform |
2022-10-10 | 開始されました | Canaccord Genuity | Buy |
2022-07-28 | 開始されました | Needham | Buy |
2022-07-18 | 開始されました | SVB Leerink | Outperform |
2022-03-11 | 開始されました | Raymond James | Outperform |
2022-03-08 | 開始されました | H.C. Wainwright | Buy |
2022-01-06 | 開始されました | William Blair | Outperform |
2021-11-18 | 開始されました | SMBC Nikko | Outperform |
2021-07-16 | 開始されました | Oppenheimer | Outperform |
2020-08-04 | 開始されました | Cowen | Outperform |
2020-08-04 | 開始されました | Evercore ISI | Outperform |
2020-08-04 | 開始されました | Mizuho | Buy |
2020-08-04 | 開始されました | Stifel | Buy |
すべてを表示
Nkarta Inc (NKTX) 最新ニュース
Charles Schwab Investment Management Inc. Cuts Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta to Participate in an April Investor Conference - GlobeNewswire
NK Cell Pioneer Nkarta Takes Center Stage at Major Healthcare Conference - Stock Titan
Leerink Partnrs Has Bullish Outlook for Nkarta Q1 Earnings - The AM Reporter
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
Nkarta: Grinding Lower, Trying To Find Support (NASDAQ:NKTX) - Seeking Alpha
Nkarta: Betting On The Turnaround (NASDAQ:NKTX) - Seeking Alpha
Leerink Partnrs Has Strong Forecast for Nkarta Q1 Earnings - Defense World
What is HC Wainwright’s Forecast for Nkarta Q1 Earnings? - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Receives $14.86 Average Price Target from Brokerages - Defense World
Stifel Nicolaus Has Lowered Expectations for Nkarta (NASDAQ:NKTX) Stock Price - Defense World
HC Wainwright Reiterates Buy Rating for Nkarta (NASDAQ:NKTX) - Defense World
Nkarta’s Strategic Workforce Reduction and Clinical Progress Justify Buy Rating - TipRanks
Analysts Adjust Price Targets For Nkarta And Bicara - Evrim Ağacı
Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday? - Benzinga
Analysts Offer Insights on Healthcare Companies: Allurion Technologies (ALUR), Perspective Therapeutics (CATX) and Nkarta (NKTX) - The Globe and Mail
Nkarta to lay off staff, senior leadership, in bid to advance autoimmune cell therapy - BioPharma Dive
Stifel cuts Nkarta stock price target to $14, maintains buy rating - Investing.com India
Nkarta to lay off 34% of staff; Savara’s debt financing deal - Endpoints News
H.C. Wainwright maintains Buy on Nkarta stock with $18 target - Investing.com
Nkarta lays off 3rd of staff to fund autoimmune CAR NK program - Fierce Biotech
Newly pivoted to autoimmune, Nkarta trims staff by over third - FirstWord Pharma
Nkarta’s Strategic Restructuring and NKX019 Progress Drive Buy Rating - TipRanks
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights - GlobeNewswire
Nkarta Posts Narrower Q4 Loss; Discloses Restructuring Plan - Marketscreener.com
Nkarta Announces Major Restructuring and Leadership Changes - TipRanks
Nkarta Inc To Reduce Workforce By 34%, Impacting 53 PositionsSEC Filing - MarketScreener
Nkarta Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Nkarta's Strategic Reset: 34% Staff Cut Powers 5-Year Cash Runway with $380M War Chest - Stock Titan
TD Cowen Keeps Their Buy Rating on Nkarta (NKTX) - The Globe and Mail
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month - MSN
Nkarta (NKTX) Loses -33.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Nkarta (NKTX) Loses -32.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Nkarta Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
Nkarta (NKTX) Projected to Post Earnings on Thursday - Defense World
NKTX stock touches 52-week low at $1.69 amid market challenges - Investing.com
Comparing Tempest Therapeutics (NASDAQ:TPST) & Nkarta (NASDAQ:NKTX) - Defense World
Will Nkarta (NASDAQ:NKTX) Spend Its Cash Wisely? - Simply Wall St
Nkarta to Participate in March Investor Conferences - The Manila Times
NKTX stock touches 52-week low at $1.96 amid market challenges - Investing.com
Leerink Partnrs Forecasts Nkarta FY2029 Earnings - MarketBeat
Leerink Partnrs Comments on Nkarta FY2024 Earnings - Defense World
Leerink Partnrs Comments on Nkarta FY2029 Earnings - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Stock Performance Spotlight: Nkarta Inc (NKTX) Ends the Day at 2.09, Down by -3.69 - The Dwinnex
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of “Buy” by Brokerages - Defense World
A new trading data show Nkarta Inc (NKTX) is showing positive returns. - SETE News
Vasculitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | R-Pharm Overseas, Abbvie, Toleranzia, Ambulero, Visterra, CytoDyn - The Globe and Mail
Monitoring Nkarta Inc (NKTX) after recent insider movements - Knox Daily
The Potential Rise in the Price of Trane Technologies plc (TT) following insiders activity - Knox Daily
Closing Figures: Nkarta Inc (NKTX)’s Negative Finish at 2.17, Down -7.26 - The Dwinnex
Nkarta Inc (NKTX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):